Following a limited submission
AWMSG advice |
|||
| Status: Not recommended | |||
Valsartan (Diovan®) tablets are not recommended for use within NHS Wales for the treatment of hypertension in children and adolescents 6 to 18 years of age. The submission contained insufficient evidence for AWMSG to recommend its use. |
|||
|
|||
Medicine details |
|||
| Medicine name | valsartan (Diovan®) | ||
| Formulation | 40 mg, 80 mg, 160 mg and 320 mg film-coated tablets and 3 mg/ml oral solution | ||
| Reference number | 671 | ||
| Indication | Treatment of hypertension in children and adolescents 6 to 18 years of age |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Assessment type | Limited | ||
| Status | Not recommended | ||
| Advice number | 0211 | ||
| NMG meeting date | 13/01/2011 | ||
| AWMSG meeting date | 16/02/2011 | ||
| Ratification by Welsh Government | 29/03/2011 | ||
| Date of issue | 31/03/2011 | ||